Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn
U.S. FDA Approves WELIREG® Plus LENVIMA® for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component
Merck's Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema
U.S. FDA Approves Update to the Label for WINREVAIR to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension
Merck Canada Partners with the Montreal Museum of Fine Arts to Present the North American Premiere of Chiharu Shiota: The Soul Trembles
Merck's KEYTRUDA QLEX Approved in Japan for Subcutaneous Administration for All KEYTRUDA® Indications Approved in Japan
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® Plus Padcev® as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer
U.S. FDA Accepts sBLA for ENFLONSIA to Update its Respiratory Syncytial Virus Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season
Health Canada Approves KEYTRUDA® for the treatment of adult patients with muscle invasive bladder cancer who are ineligible for cisplatin containing chemotherapy, in combination with enfortumab vedotin, as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline
Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
